Pages that link to "Q34416771"
Jump to navigation
Jump to search
The following pages link to Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer (Q34416771):
Displaying 50 items.
- androgen receptor (Q416601) (← links)
- Process of Fragment-Based Lead Discovery-A Perspective from NMR (Q26738768) (← links)
- Persistent androgen receptor addiction in castration-resistant prostate cancer (Q26777163) (← links)
- Open access chemical probes for epigenetic targets (Q26781872) (← links)
- KATs in cancer: functions and therapies (Q26859355) (← links)
- Targeting the adaptive molecular landscape of castration-resistant prostate cancer (Q27022821) (← links)
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors (Q27701027) (← links)
- Integrative clinical genomics of advanced prostate cancer (Q27853170) (← links)
- Epigenetic modulators as therapeutic targets in prostate cancer (Q28071912) (← links)
- Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy (Q28073470) (← links)
- The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins (Q28073961) (← links)
- Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer (Q28076086) (← links)
- Emerging data on androgen receptor splice variants in prostate cancer (Q28077830) (← links)
- aBETting therapeutic resistance by Wnt signaling (Q28081557) (← links)
- Functions of BET proteins in erythroid gene expression (Q28257378) (← links)
- Targeting BET bromodomains for cancer treatment (Q28263519) (← links)
- The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies (Q28551057) (← links)
- Prostate cancer epigenetics and its clinical implications (Q28829460) (← links)
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 (Q29547403) (← links)
- Drug Discovery Targeting Bromodomain-Containing Protein 4. (Q30352390) (← links)
- The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network. (Q31162467) (← links)
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 (Q33430717) (← links)
- Computational identification of mutually exclusive transcriptional drivers dysregulating metastatic microRNAs in prostate cancer (Q33571906) (← links)
- BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma (Q33730555) (← links)
- Exploiting Epigenetic Alterations in Prostate Cancer (Q33755160) (← links)
- The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo (Q33844624) (← links)
- BETs abet Tam-R in ER-positive breast cancer (Q34008469) (← links)
- Molecular pathways and targets in prostate cancer (Q34365632) (← links)
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. (Q34479551) (← links)
- The oxidative demethylase ALKBH3 marks hyperactive gene promoters in human cancer cells (Q34487363) (← links)
- The ETS family of oncogenic transcription factors in solid tumours. (Q34555986) (← links)
- Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation (Q34599958) (← links)
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma (Q34926232) (← links)
- The biology of castration-resistant prostate cancer (Q35039889) (← links)
- BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells (Q35574955) (← links)
- Estrogen receptor mutations and their role in breast cancer progression (Q35599448) (← links)
- Epigenomic-basis of Preemptive Medicine for Neurodevelopmental Disorders (Q35697700) (← links)
- H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription. (Q35740207) (← links)
- Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors (Q35741623) (← links)
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies (Q35842471) (← links)
- Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. (Q35920105) (← links)
- The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. (Q35921820) (← links)
- TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals (Q36021034) (← links)
- BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer (Q36053741) (← links)
- The converging roles of BRD4 and gene transcription in pluripotency and oncogenesis (Q36081650) (← links)
- Potent and selective bivalent inhibitors of BET bromodomains. (Q36172945) (← links)
- Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth (Q36185007) (← links)
- BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer (Q36211507) (← links)
- Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. (Q36213758) (← links)
- Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer (Q36328751) (← links)